







































be considered, particularly when the
patient’s symptoms persist, as described
in this case.
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(dystrophia myotonica type 1 or DM
type 1) is an autosomic dominant
disorder caused by a trinucleotide
repeat expansion, in the 30-untraslated
region of the DMPK gene (dystrophia
myotonica protein kinase) on chro-
mosome 19q13.3.1 This disorder is
characterized by myotonic phenom-
ena, progressive muscular weakness,
and wasting, involving predominantly
facial, semidistal, and distal compart-
ments. Nevertheless, patients may
show a multiorgan involvement with
abnormalities of endocrine system
(diabetes, thyroid dysfunction, hypo-
gonadism), heart system (arrhythmias,
ischemic disease, mitral valve pro-
lapse), cataract, cognitive impairment,
and mental retardation.2 Gastro-
intestinal (GI) tract may also be
involved with motility abnormalities
that can occur at any level. Small and
large bowel may be affected by a wide
range of symptoms, from chronic
constipation due to “inertia coli” to
intestinal pseudoobstruction, sigmoid
volvulus, and megacolon.3
A 37-year-old female patient with
diagnosis of DM type 1 was seen as an
outpatient in our Department for
chronic constipation and recurrent
intestinal pseudoobstruction. Myotonic
dystrophy was first diagnosed when the
patient was 25, onset symptoms being
represented by distal muscle weakness
(orbicularis and perioral muscles) and
myotonic phenomena involving hand
muscles. EMG reports, at the time of
diagnosis, showed electrical myotonia
and conduction delay. More, the pres-
ence of a familiar pattern (a brother
diagnosed as DM type 1 based on
genetic test) led to the definitive diag-
nosis. However, no significant
worsening of neuromuscular skills has
been noted from the time of diagnosis
to date. When she was 27, she devel-
oped a symptomatic hypothyroidism
that was controlled by replacement
therapy. No involvement of car-
diovascular system has been found
during these years: she has never had
clinical symptoms and ECG and echo-
cardiogram, practiced, respectively,
every 6 and 12 months since diagnosis,
have never shown any abnormality.
However, GI system involvement might
be suspected: since she was 18, she had
recurrent period of chronic constipation
(bowel movements <3/wk). In 2010,
she had an admission in a surgical
department cause of severe abdominal
pain; abdomen was distented and x-ray
showed colonic dilatation with multiple
air-fluid levels. Emergent surgery was
required: a volvulus of sigmoid colon
was found and a loop-descending
colostomy was performed. Colon
biopsy showed only submucosa edema
and a mild muscular hyperplasia.
Colostomy was reversed after 1 month
with a small partial sigmoid resection
and side to side anastomosis. A severe
chronic constipation appeared again 1
year after the operation (bowel move-
ments <1/wk) and she experienced 12
episodes of intestinal pseudoob-
structions in a 2-year time: all of them
needed admission in surgical capacities
and were treated with conservative
measures: restriction of oral intake,
nasogastric tube, intravenous fluid, and
decompressive endoscopy or rectal
probes. Maintenance therapy with daily
enemas, daily assumption of poly-
ethylene glycol preparations and proki-
netic agents (trimebutine) failed to
avoid new episodes of intestinal pseu-
doobstruction. Finally, she was seen as
outpatient at our Department asking
for a total colectomy. However, a sec-
ond-line treatment with a new proki-
netic agent (Prucalopride 2mg/die) was
attempted. The woman was reviewed in
clinic after 3 weeks. She reported that a
normal defecation, with daily stool
frequency, was restored a couple of
weeks after the beginning of the treat-
ment. Patient was suggested to keeping
up with the therapy and no changes in
the new defecation habitus have been
noted in a 6-month follow-up time, with
no more episodes of intestinal
pseudoobstruction.
DISCUSSION
GI tract is frequently involved in
Steinert myotonic dystrophy (up to
The authors declare that they have nothing to
disclose.
J Clin Gastroenterol  Volume 49, Number 1, January 2015 Letters to the Editor
r 2014 Lippincott Williams & Wilkins www.jcge.com | 85
28% of patients may be affected). It
may also be the first symptom of the
disease and sometimes it precedes
skeletal muscle involvement by 10
years; moreover, there is a low corre-
lation among the degree of GI dis-
turbances, the severity of muscle
involvement, and duration of the
disease.3
Clinical manifestations may
involve GI tract at any level3; in par-
ticular small and large bowel may be
involved with reduced or absent peri-
staltic and/or segmentary activity with
delayed intestinal transit4 leading to
chronic constipation; the clinical sce-
nario may change from diarrhea
(bacterial overgrowth due to reduced
peristaltic activity) to megacolon;
recurrent intestinal pseudoobstruction
and sigmoid volvulus due to myotonic
contractions may also occur.
The pathophysiological mecha-
nism of these digestive motor dis-
orders is not clear.
This has generally been attrib-
uted to smooth muscle damage,5 but
evidence is poor and not always sup-
ported by histologic patterns.6
Recent studies suggest that neuro-
logical alterations might play a role7: in
particular, neural dysfunctions, such as
alteration in the nonadrenergic non-
cholinergic neuronal control of the GI
tract, have been suggested7 to explain
symptoms and instrumental findings
that may be present even in the absence
of definite histologic damage; never-
theless, the degeneration of argyrophilic
neurons in the colonic myoenteric
plexus has also been found in a case of
Steinert myotonic dystrophy compli-
cated by megacolon.6
Despite its pathogenesis, chronic
constipation in these patients is usu-
ally treated with laxative, enemas, and
prokinetics.8 Cisapride, a nonselective
5-HT4 receptor agonist, has shown to
improve intestinal functions in these
patients.9 However, its arythmogenic
effect has led to its withdrawal; more,
the possibility of heart involvement in
Steinert Myotonia patients2 was also
considered an additional risk for
adverse event. Prucalopride belongs
to the class of benzofurancarbox-
amide agonists, which have high
affinity and selectivity for the 5-HT4
receptor.10 The action on this recep-
tors leads to an activation of chol-
inergic and nonadrenergic, non-
cholinergic neurotransmission by
entheric neurons11: this might explain
its effect on GI disorders in DM type
I, considering the pathogenic mecha-
nisms which were described earlier.
Safety profile regarding car-
diovascular adverse effects has been
assessed in several trials.10 This may
be due to lack of interaction with the
hERG channel or 5ht1 receptors,
which were considered to be respon-
sible for the development of adverse
cardiovascular effects with other 5-
HT4 receptor agonist.12
This is the first report, to our
knowledge, that clearly shows the
effect of prucalopride in prompt
resumption of GI symptoms in a
Steinert disease patient. Bigger series
are probably needed to confirm this
finding. This might also represent an
important step in a better under-
standing of the physiopathology and
GI disorders in Steinert myotonic
dystrophy.
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Challenges in Diagnosis and
Recognition in the United
States
To the Editor:
Chronic hepatitis E virus (HEV)
infection in immunocompromised
patients due to HIV infection, cancer
chemotherapy, and solid-organ
transplantation is unusual and is a
particularly underrecognized con-
dition.1 The lack of commercially
available, FDA-approved serologic
tests can hinder timely diagnosis. This
presents a challenge and may result in
underrecognition of chronic HEV in
populations at risk. Herein, we report
a case of chronic HEV in a renal
transplant recipient who had inde-
terminate chronic hepatitis that was
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